Ocugen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ocugen sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Ocugen: 8 sponsored US clinical trials, 2 recruiting.
Ocugen sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 3 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Retinitis Pigmentosa, with 2 trials.
Upper-quartile sponsor footprint
Ocugen sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
NCT05802329
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
NCT05956626
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
NCT06018558
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
NCT05203939
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
NCT03591874
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
NCT03785340
Dry Eye Disease Study With Brimonidine
NCT03418727
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 3 |
What is open in the Ocugen pipeline
2 recruiting of 8 indexed (25% open); 2 completed (25%).
Phase mix: 3 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Retinitis Pigmentosa (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ocugen: open-pipeline peers nationwide
Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Ocugen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 25% open enrollment (± trial volume)
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
- Advocate Hospital System · 25% recruiting · 4 trials
Related
What to do with this Ocugen page
8 registered trials is a research-attention snapshot, not an endorsement of Ocugen or any single study.
- 2 of Ocugen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Retinitis Pigmentosa is the condition Ocugen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Retinitis Pigmentosa trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ocugen pipeline card: 8 registered trials from official public datasets.Report a data error.